Tech Company Financing Transactions

Trevena Funding Round

Trevena closed a $35 million Series B financing round on 7/14/2010. Backers included New Enterprise Associates, Polaris Partners and Alta Partners.

Transaction Overview

Company Name
Trevena
Announced On
7/14/2010
Transaction Type
Venture Equity
Amount
$35,000,000
Round
Series B
Investors

New Enterprise Associates (Lead Investor) (Robert Garland)

Polaris Partners (Lead Investor) (Terry McGuire)

Alta Partners (Farah Champsi)

HealthCare Ventures (Christopher Mirabelli)

Yasuda Enterprise Development

Proceeds Purpose
Proceeds will be used to complete a Phase 2 study of Trevena's lead molecule, TRV120027, an angiotensin II type I receptor (AT1R) beta-arrestin biased ligand for treatment of acute heart failure, and to continue advancing Trevena's portfolio of GPCR biased ligands.

Company Information

Company Status
Publicly-held
Industry
Biopharmaceutical
Mailing Address
1018 West 8th Ave. A
King of Prussia, PA 19406
USA
Phone
(610) 354-8840
Website
www.trevenainc.com
Email Address
[email protected]
Overview
Trevena (NASDAQ: TRVN) is a drug discovery company focused on developing pharmaceutical products targeting G-protein coupled receptors (GPCRs).
Profile
Trevena LinkedIn Company Profile
Social Media
Trevena Company Twitter Account
Company News
Trevena News
Facebook
Trevena on Facebook
YouTube
Trevena on YouTube

Management Team

Title
Name
Email & Social
Chief Executive Officer
Maxine Gowen
  Maxine Gowen LinkedIn Profile  Maxine Gowen Twitter Account  Maxine Gowen News  Maxine Gowen on Facebook
Chief Financial Officer
Roberto Cuca
  Roberto Cuca LinkedIn Profile  Roberto Cuca Twitter Account  Roberto Cuca News  Roberto Cuca on Facebook
Chief Scientific Officer
Michael Lark
  Michael Lark LinkedIn Profile  Michael Lark Twitter Account  Michael Lark News  Michael Lark on Facebook
VP - Bus. Development
David Soergel
  David Soergel LinkedIn Profile  David Soergel Twitter Account  David Soergel News  David Soergel on Facebook
VP - General Counsel
John Limongelli
  John Limongelli LinkedIn Profile  John Limongelli Twitter Account  John Limongelli News  John Limongelli on Facebook

 

 

Browse more venture capital transactions:

Prev: 7/14/2010: XL Hybrids venture capital transaction
Next: 7/14/2010: BARRX Medical venture capital transaction

 

Share this article

 

About Database of VC Transactions

We document every notable VC transaction. VC investment data records reported here are sourced from a variety of public sources. The information is sourced from VentureDeal.com, an affiliated venture.

 

Additional Resources for Entrepreneurs

Lists of Venture Capital and Private Equity Firms

Franchise Opportunities

Contributors

Business Glossary

 

Copyright © 2001-2024. Gaebler Ventures. All rights reserved.